Tuochuang Biotechnology

Tuochuang Biotechnology is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation multi-specific antibody therapeutics for oncology and autoimmune diseases. The company leverages its proprietary T-Bio technology platform to engineer antibodies with enhanced binding affinity and specificity, aiming to overcome the limitations of current immunotherapies. Its lead programs include bispecific and multispecific antibodies targeting immune checkpoints and tumor-associated antigens. Headquartered in Suzhou, China, Tuochuang Bio maintains a robust R&D pipeline with several candidates in early-stage clinical trials and preclinical development.